Showing 1 - 10 of 1,396
Persistent link: https://www.econbiz.de/10001244101
Persistent link: https://www.econbiz.de/10002154891
Persistent link: https://www.econbiz.de/10011480271
Persistent link: https://www.econbiz.de/10012624667
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...
Persistent link: https://www.econbiz.de/10013286496
This paper investigates the short-run impact of public insurance expansion under the Affordable Care Act on out-of-pocket medical spending (OOP) and risk exposure among low-income, eligible households as well as the incidence of the cost of providing insurance. Using data from the Medical...
Persistent link: https://www.econbiz.de/10012415978
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012157261
In this paper, we examine trends in provider fees charged, government expenditure on private out-of-hospital medical services, and out of pocket costs following policy changes intended to reduce government expenditure. We examine the experience of a high-need patient group: people diagnosed with...
Persistent link: https://www.econbiz.de/10014495593
The Extended Medicare Safety Net (EMSN) in Australia was designed to provide financial assistance to patients with high out-of-pocket (OOP) costs for medical treatment. The EMSN works on a calendar year basis. Once a patient incurs a specified amount of OOP costs, the EMSN provides additional...
Persistent link: https://www.econbiz.de/10014502936
Persistent link: https://www.econbiz.de/10000884425